Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 1169

1.

Combination comet/micronucleus assay validation performed by BioReliance under the JaCVAM initiative.

Pant K, Krsmanovic L, Bruce SW, Kelley T, Arevalo M, Atta-Safoh S, Debelie F, La Force ML, Springer S, Sly J, Paranjpe M, Lawlor T, Aardema M.

Mutat Res Genet Toxicol Environ Mutagen. 2015 Jul;786-788:87-97. doi: 10.1016/j.mrgentox.2015.03.010. Epub 2015 Mar 14.

PMID:
26212297
3.

Profile of adverse drug reactions in drug resistant tuberculosis from Punjab.

Bhushan B, Chander R, Kajal NC, Ranga V, Gupta A, Bharti H.

Indian J Tuberc. 2014 Oct;61(4):318-24.

PMID:
25675695
4.

False-positive rifampicin resistance on Xpert® MTB/RIF caused by a silent mutation in the rpoB gene.

Mathys V, van de Vyvere M, de Droogh E, Soetaert K, Groenen G.

Int J Tuberc Lung Dis. 2014 Oct;18(10):1255-7. doi: 10.5588/ijtld.14.0297.

PMID:
25216843
5.

Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment.

Abate D, Tedla Y, Meressa D, Ameni G.

Int J Tuberc Lung Dis. 2014 Aug;18(8):946-51. doi: 10.5588/ijtld.13.0926.

PMID:
25199009
6.

Trends in childhood drug-resistant tuberculosis in South Africa: a window into the wider epidemic?

Schaaf HS, Hesseling AC, Rautenbach C, Seddon JA.

Int J Tuberc Lung Dis. 2014 Jul;18(7):770-3. doi: 10.5588/ijtld.13.0069.

PMID:
24902550
7.

Evaluation of Mycobacterium tuberculosis cross-resistance to isoniazid, rifampicin and levofloxacin with their respective structural analogs.

Imperiale BR, Di Giulio ÁB, Adrián Cataldi A, Morcillo NS.

J Antibiot (Tokyo). 2014 Nov;67(11):749-54. doi: 10.1038/ja.2014.61. Epub 2014 Jun 4.

PMID:
24894185
8.

Managing multidrug-resistant tuberculosis in children: review of recent developments.

Schaaf HS, Garcia-Prats AJ, Hesseling AC, Seddon JA.

Curr Opin Infect Dis. 2014 Jun;27(3):211-9. doi: 10.1097/QCO.0000000000000062. Review.

PMID:
24751893
9.

Synthesis and antitubercular screening of [(2-chloroquinolin-3-yl)methyl] thiocarbamide derivatives.

Kumar S, Upmanyu N, Afzal O, Bawa S.

Chem Biol Drug Des. 2014 Nov;84(5):522-30. doi: 10.1111/cbdd.12339. Epub 2014 Jun 3.

PMID:
24750991
10.

The Mycobacterium tuberculosis transcriptional repressor EthR is negatively regulated by Serine/Threonine phosphorylation.

Leiba J, Carrère-Kremer S, Blondiaux N, Dimala MM, Wohlkönig A, Baulard A, Kremer L, Molle V.

Biochem Biophys Res Commun. 2014 Apr 18;446(4):1132-8. doi: 10.1016/j.bbrc.2014.03.074. Epub 2014 Mar 22.

PMID:
24667600
11.

Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.

Mpagama SG, Ndusilo N, Stroup S, Kumburu H, Peloquin CA, Gratz J, Houpt ER, Kibiki GS, Heysell SK.

Antimicrob Agents Chemother. 2014;58(2):782-8. doi: 10.1128/AAC.01549-13. Epub 2013 Nov 18.

12.

High rate of hypothyroidism in multidrug-resistant tuberculosis patients co-infected with HIV in Mumbai, India.

Andries A, Isaakidis P, Das M, Khan S, Paryani R, Desai C, Dalal A, Mansoor H, Verma R, Fernandes D, Sotgiu G, Migliori GB, Saranchuk P.

PLoS One. 2013 Oct 23;8(10):e78313. doi: 10.1371/journal.pone.0078313. eCollection 2013.

13.

Structural and docking studies of potent ethionamide boosters.

Tatum NJ, Villemagne B, Willand N, Deprez B, Liebeschuetz JW, Baulard AR, Pohl E.

Acta Crystallogr C. 2013 Nov;69(Pt 11):1243-50. doi: 10.1107/S0108270113028126. Epub 2013 Oct 24.

PMID:
24192167
14.

Ion-pair chromatography for simultaneous analysis of ethionamide and pyrazinamide from their porous microparticles.

Bhanushali CJ, Zidan AS, Rahman Z, Habib MJ.

AAPS PharmSciTech. 2013 Dec;14(4):1313-20. doi: 10.1208/s12249-013-0025-3. Epub 2013 Aug 30.

15.

Estimation of content of anti-TB drugs supplied at centres of the Revised National TB Control Programme in Tamil Nadu, India.

Ramachandran G, Chandrasekaran V, Hemanth Kumar AK, Dewan P, Swaminathan S, Thomas A.

Trop Med Int Health. 2013 Sep;18(9):1141-4. doi: 10.1111/tmi.12158.

16.

Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.

Fillion A, Aubry A, Brossier F, Chauffour A, Jarlier V, Veziris N.

Antimicrob Agents Chemother. 2013 Sep;57(9):4496-500. doi: 10.1128/AAC.00506-13. Epub 2013 Jul 8.

17.

Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania.

Mpagama SG, Heysell SK, Ndusilo ND, Kumburu HH, Lekule IA, Kisonga RM, Gratz J, Boeree MJ, Houpt ER, Kibiki GS.

PLoS One. 2013 May 13;8(5):e62034. doi: 10.1371/journal.pone.0062034. Print 2013.

18.

Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection.

O'Donnell MR, Padayatchi N, Kvasnovsky C, Werner L, Master I, Horsburgh CR Jr.

Emerg Infect Dis. 2013 Mar;19(3):416-24. doi: 10.3201/eid1903.120998.

19.

Recycling and refurbishing old antitubercular drugs: the encouraging case of inhibitors of mycolic acid biosynthesis.

Belardinelli JM, Morbidoni HR.

Expert Rev Anti Infect Ther. 2013 Apr;11(4):429-40. doi: 10.1586/eri.13.24. Review.

PMID:
23566152
20.

High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations.

Machado D, Perdigão J, Ramos J, Couto I, Portugal I, Ritter C, Boettger EC, Viveiros M.

J Antimicrob Chemother. 2013 Aug;68(8):1728-32. doi: 10.1093/jac/dkt090. Epub 2013 Mar 28.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk